NCT01111422

Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients

A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Ewha Womans University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the researchers investigated the hypothesis that NAC protect peritoneal membrane damage.

Detailed description

N-Acetylcysteine (NAC) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 1200 mg per day. Patients will be randomly assigned to NAC and control group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test (PET) will be performed with blood sampling.

Conditions

• End-Stage Kidney Disease
• Peritoneal Dialysis

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-12-01
• Completion: 2011-12-01
• First posted: 2010-04-27
• Last updated: 2010-04-27

Locations

1 site across 1 country: South Korea